gastric cancer
Conditions
Interventions
Test group 1:Paclitaxel injection intraperitoneal perfusion plus intravenous chemotherapy + S-1 oral + Intravenous infusion of cindilimab injection
Sponsors
Affiliated Cancer Hospital of Shandong First Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Sign written informed consent before implementing any trial-related procedures; 2. Aged 18 to 75 years; 3. Adenocarcinoma of stomach and gastroesophageal junction confirmed by histopathological examination; 4. Diagnosed with gastric cancer and staging by laparoscopy, diagnosed with peritoneal metastasis and/or positive ascites peritoneal lavage fluid (P1 and/or CY1)), and has not received anti-tumor therapy (radiotherapy, chemotherapy, targeted or immunotherapy, etc.) ;PCI (peritoneal cancer index) 3 months; 9. Adequate organ function.
Exclusion criteria
Exclusion criteria: 1. Her-2 test is positive; 2. Known to show signs of active bleeding in the lesion under endoscopy, and have a history of gastrointestinal perforation and/or fistula within 6 months; 3. Diagnosed with malignant diseases other than gastric cancer within 5 years before the first administration (excluding basal cell carcinoma of the skin, squamous epithelial carcinoma of the skin, and/or carcinoma in situ after radical resection); 4. Currently participating in interventional clinical research treatment, or have received other investigational drugs or used investigational device treatment within 4 weeks before the first dose.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| R0 resection rate;Conversion rate of operation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of complications;Adverse reactions of immunotherapy;rate of main pathological remission; | — |
Countries
China
Contacts
Public ContactLiu Kai
Affiliated Cancer Hospital of Shandong First Medical University
Outcome results
None listed